HUTCHMED

HUTCHMED (China) Limited discovers, develops, and sells targeted therapies and immunotherapies for cancer and immunological diseases in Hong Kong, the United States, and other international markets. The company offers Fruquintinib, an oral inhibitor for vascular endothelial growth factor receptors, used to treat colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and endometrial cancer (EMC). It also provides Savolitinib, an inhibitor of mesenchymal-epithelial transition receptor, for treating NSCLC, papillary RCC, and GC. HUTCHMED develops Surufatinib for pancreatic neuroendocrine tumor (NET), non-pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib for immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat for epithelioid sarcoma and follicular lymphoma. Other developments include Fanregratinib for intrahepatic cholangiocarcinoma and Ranosidenib, a dual-inhibitor for dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes, to treat acute myeloid leukemia (AML). The company is also developing HMPL-760, currently in Phase I and II clinical trials for relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL, as well as HMPL-506 for Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutant AML. HUTCHMED collaborates with companies such as AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc. The company was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.